New stock news | Meitai Ode submits to the Hong Kong Stock Exchange for the second time

date
07:50 31/03/2026
avatar
GMT Eight
According to the disclosure by the Hong Kong Stock Exchange on March 31, Shaanxi Maikete Technology Co., Ltd. (referred to as Maikete) has once again submitted its listing application to the Main Board of the Hong Kong Stock Exchange, with Bank of China International and China Merchants Securities International as its joint sponsors. The company had previously submitted its application to the Hong Kong Stock Exchange on September 29, 2025.
According to the disclosure by the Hong Kong Stock Exchange on March 31, Shaanxi Maikai Aote Technology Co., Ltd. (referred to as Maikai Aote) has once again submitted its listing application to the Main Board of the Hong Kong Stock Exchange, with China International Capital Corporation International and CMSC International as its joint sponsors. The company had previously submitted its application to the Hong Kong Stock Exchange on September 29, 2025. The prospectus shows that the company's core product MT1013 is a self-developed, phase III dual-target receptor agonist peptide targeting both CaSR and OGP receptors, primarily designed for the treatment of secondary hyperparathyroidism, with potential to expand to other indications such as mineral and bone metabolic disorders with chronic kidney disease-mineral and bone disorder (CKD-MBD) and non-dialysis secondary hyperparathyroidism.